Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 16OTHER 8NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 9Gynecologic 1

Conditions

Recurrent Uterine Corpus Carcinoma 1

Interventions

Cisplatin 63Paclitaxel 56Carboplatin 38Taxes 24Radiotherapy 21Gemcitabine 16Brachytherapy 15Filgrastim 14Doxorubicin 13Topotecan 12Platinum 121,2-diaminocyclohexaneplatinum II citrate 12Docetaxel 11Radiation 7Granulocyte Colony-Stimulating Factor 7Chemotherapy, Adjuvant 7pegfilgrastim 6Surgical Procedures, Operative 6Radiotherapy, Intensity-Modulated 6Polymerase Chain Reaction 6Ifosfamide 6Etoposide 6Watchful Waiting 5Radiotherapy, Conformal 5Pemetrexed 5Gene Expression Profiling 5Fluorouracil 5Celecoxib 5Amifostine 5Observation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Fulvestrant × Gynecologic × Clear all
NCT00006903 2019-03-20

Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

GOG Foundation

Phase 2 Unknown
67 enrolled 9 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡